Researchers use embryonic stem cells from mice to grow motor neurons



If you think your levels of “good cholesterol” are good enough, a new study published in the December 2008 issue of The FASEB Journal suggests that you may want to think again. In the report, researchers from the University of Chicago challenge the conventional wisdom that simply having high levels of good cholesterol (HDL) and

Full Post: Poor quality HDL cholesterol bad for you

Dalhousie Medical School researchers have discovered that embryonic stem cells may play a critical role in helping people with nerve damage and motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), regain muscular strength.

Motor neurons reside in the spinal cord and control limb movements by enabling muscles to contract. Diseases like ALS cause them to degenerate, resulting in muscle weakness, atrophy, and eventual paralysis.

“This study builds on a series of studies in which we demonstrated that motor neurons can be generated from mouse embryonic stem cells,” says Dr. Victor Rafuse, associate professor of anatomy & neurobiology. “It’s very exciting that these neurons can be used for transplantation to prevent degeneration of muscle.”

The research team used embryonic stem cells from mice to grow motor neurons in the laboratory. They then transplanted the neurons into mouse nerves that were separated from the spinal cord. After separation, it would be expected that the nerves and muscles they control die. However, the Dalhousie group was the first in the world to find that the muscles not only were preserved by the transplantation, but they could produce about half their normal force to contract.

“This opens the door for a variety of different treatments,” says Dr. Rob Brownstone, professor of surgery and anatomy & neurobiology. “We’ve learned that muscles are preserved by stem cells; now we’re studying how this method can be applied to humans so that we can better treat people with nerve injuries and paralysis. Additionally, we’re looking at combining stem cell treatment with electrically-stimulated implants, which could stimulate nerves to produce movement.”

The study, which was also authored by graduate student Damien Yohn and former post-doctoral fellow Gareth Miles, was funded by New York-based Project A.L.S. It was published in today’s edition of Journal of Neuroscience .

http://www.dal.ca/

Link




The dying cells - the same type lost in patients with the devastating neurological disease spinal muscular atrophy - confirmed that the University of Wisconsin-Madison stem cell biologist had recreated the hallmarks of a genetic disorder in the lab, using stem cells derived from a patient. By allowing scientists the unparalleled opportunity to watch the

Full Post: Patient-derived induced stem cells retain disease traits



Neuralstem, Inc. announced this morning that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a clinical trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). The Company is planning to treat ALS patients through spinal injections of its stem cells via its

Full Post: Neuralstem files IND for amyotrophic lateral sclerosis stem cell trial



Researchers at the University of Southern California (USC) have identified a novel mechanism in the regulation and differentiation of neural stem cells. Researchers found that the protein receptor Ryk has a key role in the differentiation of neural stem cells, and demonstrated a signaling mechanism that regulates neuronal differentiation as stem cells begin to grow

Full Post: Discovery of mechanism that regulates the development of stem cells into neurons



Neuralstem, Inc. announced today that it has entered into a collaboration with Professor Guido Nikkah Ph.D, of Albert-Ludwigs-University in Freiburg, Germany, to advance development of Neuralstem’s human neural stem cell therapies. The collaboration with Professor Nikkah will focus on Huntington’s disease. “We are pleased to have established this collaboration in Germany” said Richard Garr, Neuralstem President

Full Post: Neuralstem enters stem cell collaboration for Huntington’s disease in Germany



Researchers have identified a stage during dopamine neuron differentiation that may be an ideal time to collect human embryonic stem cells for transplantation to treat Parkinson’s disease, according to data presented at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience. Lorraine Iacovitti, Ph.D., professor and interim director of the Farber Institute for

Full Post: Researchers identify best time for stem cell collection for Parkinson’s therapy